118 related articles for article (PubMed ID: 25637931)
1. Molecular imaging of advanced prostate cancer.
Rossi PJ; Schuster DM
Curr Probl Cancer; 2015; 39(1):29-32. PubMed ID: 25637931
[No Abstract] [Full Text] [Related]
2. Imaging in prostate cancer with multiparametric magnetic resonance imaging and gallium positron emission tomography-computed tomography: 'the real deal'?
Lawrentschuk N
BJU Int; 2015 Apr; 115 Suppl 5():1-2. PubMed ID: 25828170
[No Abstract] [Full Text] [Related]
3. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).
Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R
Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082
[TBL] [Abstract][Full Text] [Related]
4. Synchronous prostate cancer incidentally detected by FDG-PET/CT in staging a patient with newly diagnosed nasopharyngeal cancer.
Hung GU; Hsiung CY; Huang ML; Lin ST
Clin Nucl Med; 2009 Dec; 34(12):962-3. PubMed ID: 20139852
[No Abstract] [Full Text] [Related]
5. Imaging the early response to chemotherapy in advanced lung cancer with diffusion-weighted magnetic resonance imaging compared to fluorine-18 fluorodeoxyglucose positron emission tomography and computed tomography.
Tsuchida T; Morikawa M; Demura Y; Umeda Y; Okazawa H; Kimura H
J Magn Reson Imaging; 2013 Jul; 38(1):80-8. PubMed ID: 23239463
[TBL] [Abstract][Full Text] [Related]
6. [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer.
Tuncel M; Souvatzoglou M; Herrmann K; Stollfuss J; Schuster T; Weirich G; Wester HJ; Schwaiger M; Krause BJ
Nucl Med Biol; 2008 Aug; 35(6):689-95. PubMed ID: 18678354
[TBL] [Abstract][Full Text] [Related]
7. Newer imaging modalities to assist with target localization in the radiation treatment of prostate cancer and possible lymph node metastases.
John SS; Zietman AL; Shipley WU; Harisinghani MG
Int J Radiat Oncol Biol Phys; 2008; 71(1 Suppl):S43-7. PubMed ID: 18406936
[TBL] [Abstract][Full Text] [Related]
8. The pivotal role of FDG-PET/CT in modern medicine.
Hess S; Blomberg BA; Zhu HJ; Høilund-Carlsen PF; Alavi A
Acad Radiol; 2014 Feb; 21(2):232-49. PubMed ID: 24439337
[TBL] [Abstract][Full Text] [Related]
9. Molecular imaging in the framework of personalized cancer medicine.
Belkić D; Belkić K
Isr Med Assoc J; 2013 Nov; 15(11):665-72. PubMed ID: 24511645
[TBL] [Abstract][Full Text] [Related]
10. The role of PET/computed tomography scan in the management of prostate cancer.
Picchio M; Giovannini E; Messa C
Curr Opin Urol; 2011 May; 21(3):230-6. PubMed ID: 21378572
[TBL] [Abstract][Full Text] [Related]
11. Modern imaging of multiple myeloma.
Seppanen M
Acta Radiol; 2008 Jun; 49(5):487-8. PubMed ID: 18568530
[No Abstract] [Full Text] [Related]
12. Molecular imaging of prostate cancer with PET.
Jadvar H
J Nucl Med; 2013 Oct; 54(10):1685-8. PubMed ID: 24084704
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of small cell carcinoma of the prostate.
Sahiner I; Akkas BE; Ucmak Vural G
Rev Esp Med Nucl Imagen Mol; 2013; 32(3):193-5. PubMed ID: 23218515
[TBL] [Abstract][Full Text] [Related]
14. Clinical Perspective of Prostate Cancer.
Patil N; Gaitonde K
Top Magn Reson Imaging; 2016 Jun; 25(3):103-8. PubMed ID: 27187167
[TBL] [Abstract][Full Text] [Related]
15. Fluorine-18-deoxyglucose-positron emission tomography imaging with magnetic resonance and computed tomographic correlation in the evaluation of bone and soft-tissue sarcomas: a pictorial essay.
Tewfik JN; Greene GS
Curr Probl Diagn Radiol; 2008; 37(4):178-88. PubMed ID: 18502325
[TBL] [Abstract][Full Text] [Related]
16. PET/CT in prostate cancer: an unmet clinical need.
Mintz A
Oncology (Williston Park); 2014 Dec; 28(12):1065-6. PubMed ID: 25738198
[No Abstract] [Full Text] [Related]
17. Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm.
Vargas HA; Grimm J; F Donati O; Sala E; Hricak H
Eur Radiol; 2015 May; 25(5):1294-302. PubMed ID: 25693661
[TBL] [Abstract][Full Text] [Related]
18. Imaging modalities for prostate cancer.
Fütterer JJ; Barentsz J; Heijmijnk ST
Expert Rev Anticancer Ther; 2009 Jul; 9(7):923-37. PubMed ID: 19589032
[TBL] [Abstract][Full Text] [Related]
19. [Magnetic resonance imaging in the diagnosis of prostate cancer: problems and capabilities].
Revizonskaia AV; Ridén TV
Vestn Rentgenol Radiol; 2013; (5):50-6. PubMed ID: 25672154
[TBL] [Abstract][Full Text] [Related]
20. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
